1
|
Origine de la réactivation virale chez les patients transplantés rénaux avec une néphropathie à BK virus. Nephrol Ther 2021. [DOI: 10.1016/j.nephro.2021.07.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
2
|
Épidémiologie de l’infection HHV8 chez les HSH prenant la PrEP : une sous-étude de l’essai ANRS-IPERGAY. Infect Dis Now 2021. [DOI: 10.1016/j.idnow.2021.06.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Origine de la réactivation virale chez les patients transplantés rénaux avec une néphropathie à BK virus. Infect Dis Now 2021. [DOI: 10.1016/j.idnow.2021.06.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Mavacamten. Allosteric modulator of cardiac myosin, Treatment of hypertrophic cardiomyopathy, Treatment of heart failure with preserved ejection fraction. DRUG FUTURE 2021. [DOI: 10.1358/dof.2021.46.6.3273821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Firibastat. Brain aminopeptidase A inhibitor, Treatment of difficult-to-treat or resistant hypertension, Treatment of heart failure. DRUG FUTURE 2021. [DOI: 10.1358/dof.2021.46.2.3151522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
6
|
Sotorasib. GTPase KRAS (G12C mutant) inhibitor, Treatment of non-small cell lung cancer, Treatment of colorectal cancer, Treatment of solid tumors. DRUG FUTURE 2021. [DOI: 10.1358/dof.2021.46.7.3301489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Vamorolone. Delta-9,11 Glucocorticoid analogue, Dissociative steroid, Treatment of Duchenne muscular dystrophy. DRUG FUTURE 2021. [DOI: 10.1358/dof.2021.46.8.3293586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Berotralstat. Plasma kallikrein (KLKB1) inhibitor, Treatment of hereditary angioedema attacks. DRUG FUTURE 2021. [DOI: 10.1358/dof.2021.46.1.3220730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Daridorexant. Dual orexin OX1/OX2 receptor antagonist, Treatment of sleep disorders. DRUG FUTURE 2020. [DOI: 10.1358/dof.2020.45.10.3168442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Onvansertib fumarate. Serine/threonine-protein kinase, PLK1 (STPK13) inhibitor, Treatment of prostate cancer, Treatment of colorectal cancer, Treatment of acute myeloid leukemia. DRUG FUTURE 2020. [DOI: 10.1358/dof.2020.45.1.3077342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Etrasimod arginine. Sphingosine-1-phosphate receptor 1 (S1P1 receptor) agonist, Treatment of ulcerative colitis. DRUG FUTURE 2020. [DOI: 10.1358/dof.2020.45.3.3093451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
12
|
Narsoplimab. Anti-mannan-binding lectin-associated serine protease 2 (MASP-2) antibody, Treatment of transplant-associated thrombotic microangiopathies, Treatment of IgA nephropathy. DRUG FUTURE 2020. [DOI: 10.1358/dof.2020.45.5.3115213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
13
|
Loncastuximab tesirine. Antibody-drug conjugate targeting B-cell specific surface protein CD19, Treatment of hematological malignancies. DRUG FUTURE 2020. [DOI: 10.1358/dof.2020.45.8.3158046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Resmetirom. Thyroid hormone receptor-beta agonist, Treatment of nonalcoholic steatohepatitis. DRUG FUTURE 2020. [DOI: 10.1358/dof.2020.45.12.3191006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Experience abroad and participation in ESCMID educational activities: results from a survey among French infectious diseases specialists in training. Clin Microbiol Infect 2019; 26:388-390. [PMID: 31678232 DOI: 10.1016/j.cmi.2019.10.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2019] [Revised: 10/17/2019] [Accepted: 10/21/2019] [Indexed: 10/25/2022]
|
16
|
Facteurs de risque et pronostic des infections à norovirus en transplantation rénale. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Expérience de formation à l’étranger : résultats d’une enquête auprès des jeunes infectiologues français. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Cenobamate. Drug acting on GABAA receptors, Antiepileptic drug. DRUG FUTURE 2019. [DOI: 10.1358/dof.2019.44.8.3030644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Ubrogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine. DRUG FUTURE 2019. [DOI: 10.1358/dof.2019.44.11.3035581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Avapritinib. PDGFR-alpha and KIT mutant inhibitor, Treatment of gastrointestinal stromal tumor, Treatment of systemic mastocytosis. DRUG FUTURE 2019. [DOI: 10.1358/dof.2019.44.3.2970912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Idasanutlin. MDM2 (Hdm2) inhibitor, Treatment of acute myeloid leukemia, Hematological cancer therapy. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.02.2743593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
22
|
|
23
|
Rovalpituzumab tesirine. Antibody-drug conjugate targeting delta-like protein 3 (DLL3), Treatment of small cell lung cancer. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.04.2781506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
24
|
Bemcentinib. Tyrosine-protein kinase receptor UFO (Axl) inhibitor, Treatment of cancer. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.09.2808543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
25
|
Telaglenastat. Glutaminase inhibitor, Treatment of advanced solid tumors. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.12.2869764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Varlitinib tosylate. Pan-HER tyrosine kinase inhibitor, Treatment of cancer. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.11.2817971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Savolitinib. Hepatocyte growth factor receptor (HGFR, MET, c-Met) inhibitor, Cancer therapy. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.01.2754012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. Drugs Today (Barc) 2017; 50:729-37. [PMID: 25525633 DOI: 10.1358/dot.2014.50.11.2233783] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Acute bacterial skin and skin structure infections (ABSSSI) are associated with remarkable morbidity, and often require hospitalization. The cause of most ABSSSI is aerobic Gram-positive cocci, including Staphylococcus aureus, and β-hemolytic streptococci. Tedizolid phosphate is a novel oxazolidinone prodrug whose active moiety is tedizolid. It has shown potent in vitro activity against Gram-positive pathogens, encompassing methicillin-resistant S. aureus (MRSA) and strains resistant to vancomycin or linezolid. Animal studies suggested bactericidal activity in vivo. Pharmacokinetic studies demonstrated a good penetration into skin and soft tissues, and suitability for once-daily administration, either orally or intravenously at the same dosage. Pivotal phase III studies showed that tedizolid phosphate at 200 mg once daily for 6 days is noninferior to linezolid 600 mg twice daily for 10 days in ABSSSI patients, whereas gastrointestinal disorders were less frequent with tedizolid phosphate than linezolid. Tedizolid phosphate has been approved by the U.S. FDA, as Sivextro® to treat adult patients with ABSSSI.
Collapse
|
29
|
Human monocytes downregulate innate response receptors following exposure to the microbial metabolite n-butyrate. IMMUNITY INFLAMMATION AND DISEASE 2017; 5:480-492. [PMID: 28681454 PMCID: PMC5691313 DOI: 10.1002/iid3.184] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 05/26/2017] [Accepted: 06/12/2017] [Indexed: 12/23/2022]
Abstract
Introduction Hyporesponsiveness of human lamina propria immune cells to microbial and nutritional antigens represents one important feature of intestinal homeostasis. It is at least partially mediated by low expression of the innate response receptors CD11b, CD14, CD16 as well as the cystine‐glutamate transporter xCT on these cells. Milieu‐specific mechanisms leading to the down‐regulation of these receptors on circulating monocytes, the precursor cells of resident macrophages, are mostly unknown. Methods Here, we addressed the question whether the short chain fatty acid n‐butyrate, a fermentation product of the mammalian gut microbiota exhibiting histone deacetylase inhibitory activity, is able to modulate expression of these receptors in human circulating monocytes. Results Exposure to n‐butyrate resulted in the downregulation of CD11b, CD14, as well as CD16 surface expression on circulating monocytes. XCT transcript levels in circulating monocytes were also reduced following exposure to n‐butyrate. Importantly, treatment resulted in the downregulation of protein and gene expression of the transcription factor PU.1, which was shown to be at least partially required for the expression of CD16 in circulating monocytes. PU.1 expression in resident macrophages in situ was observed to be substantially lower in healthy when compared to inflamed colonic mucosa. Conclusions In summary, the intestinal microbiota may support symbiosis with the human host organism by n‐butyrate mediated downregulation of protein and gene expression of innate response receptors as well as xCT on circulating monocytes following recruitment to the lamina propria. Downregulation of CD16 gene expression may at least partially be caused at the transcriptional level by the n‐butyrate mediated decrease in expression of the transcription factor PU.1 in circulating monocytes.
Collapse
|
30
|
Caractéristiques cliniques et pronostic des spondylodiscites à pyogènes chez les sujets âgés de plus de 75 ans. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.212] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Guselkumab. Anti-IL-23 antibody, Antipsoriatic. DRUG FUTURE 2017. [DOI: 10.1358/dof.2017.042.02.2564098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
32
|
Enasidenib mesylate. Isocitrate dehydrogenase (NADP+), (IDPm, IDH2) inhibitor, Treatment of acute myeloid leukemia. DRUG FUTURE 2017. [DOI: 10.1358/dof.2017.042.01.2579894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Ivosidenib. Isocitrate dehydrogenase (IDH) inhibitor, Treatment of hematological cancer, Treatment of solid tumors. DRUG FUTURE 2017. [DOI: 10.1358/dof.2017.042.10.2687523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Daprodustat. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, Treatment of anemia
associated with chronic kidney disease. DRUG FUTURE 2017. [DOI: 10.1358/dof.2017.042.06.2630604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
35
|
Glasdegib. Hedgehog signaling inhibitor, Treatment of myelodysplastic syndrome, Treatment of chronic myelomonocytic leukemia, Treatment of acute myeloid leukemia, Treatment of myelofibrosis. DRUG FUTURE 2017. [DOI: 10.1358/dof.2017.042.05.2618154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Un phénomène de Koebner exceptionnel. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
MYCOBACT-11 - Caractéristiques des tuberculoses chez les patients transplantés rénaux dans un CHU entre 2004 et 2015 : à propos de 15 cas. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30457-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
|
39
|
Emicizumab. Anti-factor IXa and X monoclonal antibody, Treatment of congenital FVIII deficiency (hemophilia A). DRUG FUTURE 2016. [DOI: 10.1358/dof.2016.041.11.2555983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
40
|
Pradigastat. Diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor, Treatment of lipoprotein disorders. DRUG FUTURE 2016. [DOI: 10.1358/dof.2016.041.02.2443235] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
41
|
Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 2015; 13:293-302. [PMID: 25403270 DOI: 10.1111/jth.12790] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Indexed: 08/31/2023]
Abstract
BACKGROUND Cardiac involvement is a major cause of mortality in patients with thrombotic thrombocytopenic purpura (TTP). However, diagnosis remains underestimated and delayed, owing to subclinical injuries. Cardiac troponin-I measurement (cTnI) on admission could improve the early diagnosis of cardiac involvement and have prognostic value. OBJECTIVES To assess the predictive value of cTnI in patients with TTP for death or refractoriness. PATIENTS/METHODS The study involved a prospective cohort of adult TTP patients with acquired severe ADAMTS-13 deficiency (< 10%) and included in the registry of the French Reference Center for Thrombotic Microangiopathies. Centralized cTnI measurements were performed on frozen serum on admission. RESULTS Between January 2003 and December 2011, 133 patients with TTP (mean age, 48 ± 17 years) had available cTnI measurements on admission. Thirty-two patients (24%) had clinical and/or electrocardiogram features. Nineteen (14.3%) had cardiac symptoms, mainly congestive heart failure and myocardial infarction. Electrocardiogram changes, mainly repolarization disorders, were present in 13 cases. An increased cTnI level (> 0.1 μg L(-1) ) was present in 78 patients (59%), of whom 46 (59%) had no clinical cardiac involvement. The main outcomes were death (25%) and refractoriness (17%). Age (P = 0.02) and cTnI level (P = 0.002) showed the greatest impact on survival. A cTnI level of > 0.25 μg L(-1) was the only independent factor in predicting death (odds ratio [OR] 2.87; 95% confidence interval [CI] 1.13-7.22; P = 0.024) and/or refractoriness (OR 3.03; 95% CI 1.27-7.3; P = 0.01). CONCLUSIONS A CTnI level of > 0.25 μg L(-1) at presentation in patients with TTP appears to be an independent factor associated with a three-fold increase in the risk of death or refractoriness. Therefore, cTnI level should be considered as a prognostic indicator in patients diagnosed with TTP.
Collapse
|
42
|
Abituzumab. Anti-integrin alpha-nu (CD51, ITGAV) MAb, Oncolytic. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.040.02.2264075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Binimetinib. MEK 1/2 inhibitor, Treatment of NRAS-mutated melanoma, Treatment of ovarian cancer. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.040.03.2297483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
44
|
Rociletinib hydrobromide. Irreversible inhibitor of mutant EGFR, treatment of NSCLC. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.040.01.2258365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
45
|
Ozanimod. Sphingosine 1-phosphate receptors 1 and 5 (S1P1 and S1P5) modulator, Treatment of multiple sclerosis, Treatment of inflammatory bowel disease. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.40.9.2387228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
46
|
TEV-48125. Anti-CGRP MAb, Antimigraine. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.040.12.2424881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
47
|
Brigatinib. ALK and mutant EGFR inhibitor. Treatment of NSCLC. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.040.05.2273387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
48
|
Sodium zirconium cyclosilicate. Potassium (K+) ion trap, treatment for hyperkalemia. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.40.7.2319756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Lucitanib hydrochloride: Dual FGFR/VEGFR inhibitor Treatment of NSCLC and breast cancer. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.040.08.2345416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023]
|
50
|
AQX-1125. DRUG FUTURE 2015. [DOI: 10.1358/dof.2015.040.06.2302827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|